Will the Bengals rookie QB throw an interception vs. the Steelers?
Will the Bengals rookie QB throw an interception vs. the Steelers?
We hereby announce that election of an employee representative to the board of directors of Gabriel Holding A/S was held on 30 November 2020. Sales Supporter in Customer Service, Quinten Van Dalm, has been re-elected as employee representative on Gabriel Holding A/S' board of directors for a 4-year period with appointment immediately after the company's annual general meeting on 10 December 2020. Attachment * Gabriel Holding AS - Announcement no 17 - Election of employee representative for the board of directors
Online reviews are an excellent way for property owners to get feedback on their vacation rentals. Reviews from past guests -- especially five-star ones -- are one of the best ways to attract new renters and keep your rental booked all season. A review aggregator can make a world of difference in your vacation property bookings.
PARIS, Dec 1 (Reuters) - "Chez Francoise" is a discreetly located venue near the French parliament whose visitors' book boasts signatures from former leaders including Nicolas Sarkozy and Francois Hollande. In late September, as a second wave of COVID-19 infection loomed, government scientific advisers wanted new restrictions on bars, restaurants and cafes. Fearing his business would suffer, Pascal Mousset, who owns Chez Francoise and four other restaurants in the French capital, decided to seek help from an old contact.
New survey shows healthcare workers—and nurses in particular—are anxious, overwhelmed, physically and emotionally burned out, and worried about exposing loved onesAlexandria, VA, Dec. 01, 2020 (GLOBE NEWSWIRE) -- As the number of COVID-19 cases continue to rise across the nation at a record-breaking speed and hospitals become overwhelmed, the pandemic is taking a dangerous toll on the mental health of frontline healthcare workers, according to a new survey conducted by Mental Health America (MHA) with funding from the Johnson & Johnson Foundation.“Health care workers have been thrust onto the front lines, exposed to a deadly virus daily,” said Paul Gionfriddo, president and CEO of MHA. “With the skyrocketing number of COVID-19 cases, it is getting worse by the day and healthcare workers aren’t getting a reprieve. They are frustrated, anxious, overwhelmed, burned out and worried about exposing their loved ones, nurses in particular. We need to make sure that we are taking care of healthcare workers so they can take care of us.”The study showed that healthcare workers are: * Stressed out and anxious: 93% of health care workers were experiencing stress, 86% reported experiencing anxiety, 77% reported frustration, 76% reported exhaustion and burnout, and 75% said they were overwhelmed. * Worried about exposing loved ones: 76% of healthcare workers reported that they were worried about exposing their child to COVID-19, nearly half were worried about exposing their spouse or partner and 47% were worried about exposing their older adult family member(s). * Emotionally and physically exhausted: Emotional exhaustion was the most common answer for how healthcare workers were feeling (82%), followed by trouble with sleep (70%), physical exhaustion (68%) and work-related dread (63%). Over half selected change in appetite (57%), physical symptoms like headaches or stomachaches (56%), questioning their career path (55%), compassion fatigue (52%) and heightened awareness or attention to being exposed to COVID-19 (52%). Nurses reported having a higher exposure to COVID-19 (41%) and they were more likely to feel too tired (67%) compared to other healthcare workers (61%). * Not getting enough emotional support: 39% of healthcare workers said that they did not feel like they had adequate emotional support. Nurses were even less likely to have emotional support (45%). * Struggling with parenting: Among people with children, half reported they are lacking quality time or are unable to support children or be a present parent.MHA says stress if left untreated can lead to more severe mental health conditions such as depression, anxiety, psychosis and even thoughts of suicide or self-harm, or Stage 4. MHA says that the best way to avoid a mental health crisis – referred to as “Before Stage 4”– is to prevent it altogether. To do this, MHA says it is critical to identify signs of anxiety and depression early on and intervene quickly.MHA teamed up with the Johnson & Johnson Center for Health Worker Innovation to listen to the needs of healthcare workers and developed a library of resources for healthcare workers which can be accessed at MHAnational.org/frontline. The library includes webinars, resources for getting sleep, coping with fear, finding emotional support, dealing with burnout and overwhelm, and coping with contracting COVID-19.“Most healthcare workers fully understand the stress of working in a high-risk environment,” said Russell C. Petrella, Ph.D., a clinical psychologist and MHA Board member. “However, the pandemic has presented new and overwhelming challenges on a daily basis. Given the relentless pressures on these professionals, it is not surprising that some burnout occurs. Every hospital and healthcare system treating COVID-19 patients needs to have supports and mental health resources readily available for healthcare workers to access.”Across the board, MHA has seen alarming increases in reports of depression and anxiety nationwide. A report released in October 2020 showed that more than 1.5 million people who took a screening at MHAscreening.org reported signs of anxiety and/or depression, with Sept. reporting the highest rate of severity since the start of the pandemic. Anxiety screenings were up by 634% from January and depression screenings were up 873%.“We collectively see glimmers of hope on the horizon with a vaccine and more effective treatments for COVID-19,” said Gionfriddo. “But right now, we need to focus on supporting our healthcare workers in getting through this new wave of infections so that they can see to the other side. Even when a vaccine is created, many healthcare workers may experience PTSD, which we also need to pay attention to.” If you are a healthcare worker and believe you are experiencing anxiety or depression, go to mhanational.org/frontline to be screened and find resources and support. If you are experiencing a mental health crisis, call 1-800-273-TALK (8255) to reach a 24-hour crisis center, text MHA to 741741, call 911, or go to the nearest emergency room. Go to MHAnational.org to learn more. Read the full survey results here. About Mental Health AmericaMental Health America (MHA) is the nation’s leading community-based nonprofit dedicated to addressing the needs of those living with mental illness and promoting the overall mental health of all. MHA’s work is driven by its commitment to promote mental health as a critical part of overall wellness, including prevention services for all; early identification and intervention for those at risk; integrated care, services, and supports for those who need them; with recovery as the goal. Learn more at MHAnational.org CONTACT: Ariane Le Chevallier Mental Health America 9712011214 firstname.lastname@example.org
Industry leader continues successful growth strategy with 16th acquisitionTampa, FL, Dec. 01, 2020 (GLOBE NEWSWIRE) -- DAS Health Ventures, Inc., an industry leader in health IT and management, announced today it completed the acquisition of Randall Technology Services, LLC (RandallTech) a healthcare and managed IT company based in Amarillo, TX. As part of DAS’ growth strategy, this most recent expansion further strengthens their position in the US healthcare technology space.DAS Health actively serves more than 1,800 clients, and nearly 3,500 clinicians and 20,000 users nationwide, with offices in Florida, Nevada, New Hampshire and Texas, and a significant employee presence in 14 key states. This acquisition adds Allscripts® PM and EHR solutions to the DAS portfolio of supported products, and DAS Health has now added additional staff in Texas that will create opportunities for greater regional support of its entire solutions portfolio.“We are continuously growing and working towards providing additional benefits for new and existing clients.” stated David Schlaifer, DAS Health President and CEO. “We are excited to bring our additional suite of services to the RandallTech clients, and to bring the RandallTech solutions and team members into the DAS family, as we continue to strengthen our existing presence.”“We are thrilled to be joining the DAS Health family. This acquisition will provide new levels of support for our clients.” said Randy Whipple, Owner of Randall Technology Services; “I am confident that our clients and employees will have nothing but continuing success with DAS.”Randall Technology’s clients will gain an increased depth of support, and a substantially improved value proposition, as DAS Health’s award-winning offerings are robust, including managed IT / MSP services, practice management and EHR software sales, training, support and hosting, revenue cycle management (RCM), security risk assessments (SRA), cybersecurity, MIPS/MACRA reporting & consulting, mental & behavioral health screenings, chronic care management, telemedicine, and other value-based and patient engagement solutions. About DAS HealthDAS Health has been a leading provider of Health IT and management solutions and a trusted consultant to independent physician groups, hospitals and healthcare systems across North America since 2003. Headquartered in Tampa, FL, with regional offices in Las Vegas, New Hampshire and Texas, and employees in 14 states, DAS delivers superior Information Technology, MSP, RCM medical billing, value-based care, patient engagement, compliance, and practice management solutions for nearly 20,000 users nationwide. It includes representation and support of various Practice Management and EHR platforms, including NextGen® Office, Henry Schein MicroMD®, and now Allscripts®, and is the largest reseller of Aprima® and e-MDs’ Lytec, Medisoft, and Practice Partner solutions; providing numerous other services in conjunction with AdvancedMD®, Athenahealth®, eClinicalWorks™, GreenwayHealth™, and many other platforms. Visit DAShealth.com to learn more. www.DAShealth.com Aprima® is a registered trademark of Aprima Medical Software, Inc., an eMDs Company; eMDs, eMDs Plus, Lytec, Practice Partner and Medisoft are trademarks of eMDs, Inc. NextGen® Office is a registered trademark of QSI Management, LLC. MicroMD® is a registered trademark of Henry Schein Medical Systems, Inc. AdvancedMD® is a registered trademark of AdvancedMD, Inc. Athenahealth® is a registered trademark of Athenahealth, Inc. Allscripts® is a registered trademark of Allscripts Healthcare Solutions, Inc. eClinicalWorks™ is a trademark of eClinicalWorks, LLC. GreenwayHealth™ is a trademark of Greenway Health, LLC. Media ContactJulianne Porter | Vice President of Client Success Julianne.Porter@DAShealth.com | 813-774-9800 x 200
STRATHROY, Ontario, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Eve & Co Incorporated (“Eve & Co”, “we”, “us” or the “Company”) (TSX-V: EVE; OTCQX: EEVVF) is pleased to announce that its wholly-owned subsidiary, Natural MedCo Ltd. (“NMC”), successfully shipped its first order of cannabis-infused bath bombs to the Ontario Cannabis Store (“OCS”) this month. Eve & Co has shipped two of its cannabis-infused bath bomb products, The Boss and The Dreamer. These products are the first of their kind to market as well as the first product launch in the Company’s cannabis 2.0 line of female-focussed products in Ontario.The Eve & Co cannabis-infused bath bombs are manufactured by a woman-led team within the Company’s 1,000,000 square foot greenhouse facility in Strathroy, Ontario. The products are individually hand made with a full spectrum distillate extracted from the Company’s sun-grown cannabis and are formulated to include specific terpene and aromatic properties.The BossThe Boss bath bomb is infused with natural lemon, grapefruit and sweet orange essential oils and is meant to empower you to take on all challenges with exceptional boldness.The DreamerThe Dreamer bath bomb is infused with natural lavender and chamomile essential oils and is meant to calm the soul and soothe the body at the end of a long day.“We couldn’t be more excited to be launching our cannabis-infused bath bomb products in our home province just in time for the holiday season. Our bath bomb production team, endearingly known as our “bombers”, have worked tirelessly to get these wonderful products to market for Ontarians to enjoy, especially as we are all spending more time than ever at home this winter,” said Melinda Rombouts, President and Chief Executive Officer of Eve & Co.ABOUT EVE & CO Eve & Co, through its wholly-owned subsidiary NMC, holds cultivation and processing licences under the Cannabis Act (Canada) for the production and sale of various cannabis products, including dried cannabis, cannabis plants and extraction of cannabis oil and has received its European Union certificate of Good Manufacturing Practice. NMC was Canada’s first female-founded licensed producer of medicinal marijuana and received its cultivation licence from Health Canada in 2016. Eve & Co is led by a team of agricultural experts and has a licensed 1,000,000 square foot greenhouse located in Strathroy, Ontario. The Company’s website can be visited at www.evecannabis.ca.Neither the CSE and TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur, and include, but are not limited to, the production and sale of bath bombs by the Company, whether sales of bath bombs will occur, if any at all, or recur and the timing thereof. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements and readers should not place undue reliance on such statements. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements, including general business and economic conditions, changes in laws and regulations, product demand, changes in prices of required commodities, competition, the effects of and responses to the COVID-19 pandemic and other risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's management’s discussion and analysis dated November 26, 2020 (the "MD&A") and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR at www.sedar.com. The Company cautions that the list of risks, uncertainties and other factors described in the MD&A is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. These forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law.For further information, please contact: Melinda Rombouts President and Chief Executive Officer Eve & Co Incorporated Telephone: (855) 628-6337Rory Taylor Interim Chief Financial Officer Eve & Co Incorporated Telephone: (855) 628-6337
As vice president, Kamala Harris will have the ear of the president and play an instrumental role in determining what policy goals President-elect Joe Biden pursues. As a senator, Harris aimed to tackle the problem of expensive housing with an act called the Rent Relief Act. Under the act, taxpayers would be eligible to receive refundable tax credits if their rent and utilities exceed 30% of their household income.
VANCOUVER, British Columbia, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Choom Holdings Inc. (“Choom” or the “Company”) (CSE: CHOO; OTCQB: CHOOF), a fast-expanding retail cannabis company that has established one of the largest store networks in Canada, is pleased to report its financial and operating results for the first quarter of fiscal 2021 ending September 30, 2020. First Quarter Financial Highlights: * Q1 2021 revenue of $6.1M • Increase of $2M and 50% over Q4 2020 revenue of $4.1M * Q1 2021 Gross Margin of 36.33% • Increase of 3.06% over Q4 2020 gross margin of 33.26% * Q1 2021 G&A of $1M or 15.74% of revenue • Versus $1.2M or 28.68% of revenue Q4 2020 * Q1 2021 Salary and Wages of $1.1M or 18.24% of revenue • Versus $0.8M or 20.17% of revenue Q4 2020First Quarter Divisional Highlights:Finance: Choom continues to make strides in our strategic path to profitability, increasing sales while right sizing expenditures, improving margins, and inventory efficiency through our centralized product team resulting in positive adjusted EBITDA 1 for the quarter of $35K.Operations: As we move forward with our new store growth strategy, ground has broken in Yaletown, Vancouver, with an opening set for January 2021. Additionally, a 4th development permit was secured in Vancouver, further creating defensibility amongst other national competitors.During the quarter, we re-opened the Westlock store location that had been previously closed due to COVID-19. Additionally, in Q2 we re-opened Camrose 48th, another location that was previously closed, bringing our open and operating store count to 14.Brand:Choom’s marketing vision receives industry recognition, with nominations for three prestigious awards by ADCANN this November: Storefront Brand of the Year, Marketer of the Year and Best Social Media of the year. Our digital development also continues as we enhance our industry-leading technology on Choom’s 2.0 digital platform, further positioning ourselves as a technology enabled Cannabis retailer, supporting our strategic pillar of creating a true omni-channel experience.Culture:The further centralization of our business model continues to attract top talent both at our store support center as well as at our retail locations. Work continues to bring key functions of our team in-house, reducing reliance and costs related to contractors and consultants, allowing for improved business support.About Choom™Choom™ is a fast-expanding retail cannabis company that has established one of the largest store networks in Canada. The Choom brand is inspired by Hawaii's “Choom Gang”—a group of buddies in Honolulu during the 1970's who loved to smoke weed—or as the locals called it, “Choom”. Evoking the spirit of the original Choom Gang, our brand caters to the Canadian market with the ethos of ‘cultivating good times’. Choom™ is focused on delivering an elevated customer experience through our curated retail environments, offering a diversity of brands for Canadians across a national retail network. Cautionary Statement on Forward-looking information This news release contains forward-looking information relating to the Company's proposed activities and other statements that are not historical facts. Forward-looking information relates to management's future outlook and anticipated events or results and includes statements or information regarding the future plans or prospects of the Company. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. These factors include risks and uncertainties associated with or arising as a result of delays in obtaining or an inability to obtain required regulatory approvals, access to sufficient quantities of cannabis, the results of diligence investigations, the actions of third parties, the results of negotiations with third parties, developments in the cannabis sector, the ability to access sufficient capital from internal and external sources, reliance on key personnel, regulatory risks and delays and other risks and uncertainties discussed in the management discussion and analysis section of the Company's interim and most recent annual financial statement or other reports and filings, including those made with the CSE and applicable Canadian securities regulators. There can be no assurance that such forward looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward looking information. 1: Non-IFRS Measures – Adjusted EBITDA Adjusted EBITDA is a Non-IFRS metric used by management and does not have any standardized meaning prescribed by IFRS. The metric may not be comparable to similar measures presented by other companies. Management defines Adjusted EBITDA as the Income (loss) for the period, as reported, before accretion, interest, tax, share-based compensation, depreciation and amortization, impairment, gains and losses related to the disposition of tangible assets, debt extinguishments and professional fees associated with financing and acquisition activities. Management believes Adjusted EBITDA is a useful financial metric to assess its operating performance.NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAS REVIEWED OR ACCEPTED RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE. CONTACT: For additional information contact: Corey Gillon, CEO Telephone: 604-683-2509 Chris Bogart, President Telephone: 604-683-2509 email@example.com
Low-Cost Low-Power Sensors and Flexible Network Options Provide Utilities with New Approach to Rapidly Execute Digitization and Safety PlansPORTSMOUTH, N.H., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Senet, Inc., a leading provider of cloud-based software and services platforms that enable global connectivity and on-demand network build-outs for the Internet of Things (IoT), today announced it is collaborating with CNIguard and Semtech Corporation (Nasdaq: SMTC) to deliver natural gas monitoring solutions to utilities across the United States. Through this partnership, the companies are addressing the utility industry’s digitization requirements by providing an intelligent network infrastructure designed to support a massive ecosystem of utility-centric LoRaWAN devices for gas safety and service delivery. Starting with gas safety, the companies are collaborating to introduce a new version of CNIguard’s GasMarshal methane sensor which integrates Semtech’s LoRa® devices and the LoRaWAN® protocol. The CNIguard network-connected gas leak detection solution supports accurate, maintenance-free operation with service level agreements (SLAs) over 10 years due to the market leading power efficiency of its battery-operated devices. CNIguard will also be integrating its solution with Senet’s LoRaWAN network - the largest public, SLA-backed carrier-grade LoRaWAN network in the United States. Offering extensive flexibility to utilities, Senet provides options for public, private and semi-private network deployment and network operation. The low total cost of ownership (TCO) delivered by the efficiencies of devices developed with the LoRaWAN protocol, coupled with flexible network deployment models, are enabling new levels of operational efficiency and rate payer affordability.“We’re excited to be working with Senet and Semtech to develop sensor-enabled devices and solutions that will help modernize critical infrastructure, enhance safety and improve overall operational efficiency for utilities,” said Edward Klinger, CEO at CNIguard. “Our utility customers are investing in the technologies that will enable the next generation of energy systems and we view supporting the LoRaWAN protocol as a critical element of that process.”Executing a collaborative go-to-market strategy, CNIguard, Senet and Semtech are engaged in field trials with large multi-utility service providers to explore use cases focused on improving safety levels and reliability across regional distribution networks. Extending value further, with a Senet network in place for gas leak detection, utilities can easily add network capacity and coverage to enhance operations and expand their service offerings to include other gas safety and service delivery solutions on the same IoT network.“Senet has commercially deployed dense LoRaWAN networks in municipalities across the United States to support AMI for water metering and water management applications, and opportunities in the natural gas market are following close behind,” said Bruce Chatterley, CEO at Senet. “We look forward to a successful partnership with CNIguard in support of this growing market opportunity and are excited to be teamed with Semtech and CNIguard to deliver new levels of commercial and consumer safety through IoT connected solutions.”“Carrier-grade network connectivity from Senet and highly reliable low-cost sensors based on the LoRaWAN protocol from CNIguard provide utilities with new models of control and the ability to drive their vision of automation and digitization faster than ever before,” said Marc Pegulu, Vice President of IoT Product Marketing at Semtech’s Wireless Sensing Business. “With these solutions available today, utilities are in a unique position to become leading adopters of large scale IoT solutions that will have a lasting positive impact on the safety of citizens, the modernization of municipal infrastructure, and resource conservation.”According to the U.S. Energy Information Administration, nearly half of all homes in the United States use natural gas as their primary heat source and, although it may seem rare, the Pipeline and Hazardous Materials Safety Administration reports explosion accidents involving natural gas pipelines occur once every two days. Statistics from NFPA publications and reports from the National Transportation Safety Board (NTSB) show that most major gas incidents in the United States involve some type of leak, resulting in an average of 40 deaths, 140 civilian injuries and over $50 million in direct property damage per year. For utilities, mitigating and ultimately eliminating these incidents and ensuring the safe, efficient, and environmentally sound distribution of natural gas to residential and commercial consumers is of paramount concern. In addition to enhancing consumer safety, these solutions assist utilities in supporting existing and expected legislative regulations focused on gas leak detection and remediation processes.About Senet, Inc. Senet develops cloud-based software and services used by Network Operators, Application Developers, and System Integrators for the on-demand deployment of Internet of Things (IoT) networks. In addition to industrial and commercial applications, Senet has designed smart meter networks for many municipal water utility districts across North America, representing millions of households. With a multi-year head start over competing Low Power Wide Area Network technologies, Senet offers technology in over eighty countries and owns and operates the largest publicly available LoRaWAN network in North America. Our disruptive go-to-market models and critical technical advantages have helped us become a leading connectivity provider with recognized expertise in building and operating global IoT networks. For additional information, visit www.senetco.com.About CNIguard CNIguard is a high technology firm delivering infrastructure protection, public & worker safety and asset management solutions to the energy, electricity, water, transportation and other vital sectors. In an era of Big Data and the Industrial Internet of Things (IIOT), through our SensorCore® platform, CNIguard solutions enable the monetization of data. Our devices that include Sentir (Manhole Monitoring System), GasMarshal (Gas Monitoring System), InDetect (Intrusion Detection System) and OverLine (Overhead Line Monitoring System), are embedded into transmission and distribution networks and comprise diverse sensors in a ruggedized design, with long life battery or power harvesting, and simple, rapid installation. For additional information, visit https://www.cniguard.com/About Semtech Semtech Corporation is a leading supplier of high-performance analog and mixed-signal semiconductors and advanced algorithms for infrastructure, high-end consumer and industrial equipment. Products are designed to benefit the engineering community as well as the global community. The Company is dedicated to reducing the impact it, and its products, have on the environment. Internal green programs seek to reduce waste through material and manufacturing control, use of green technology and designing for resource reduction. Publicly traded since 1967, Semtech is listed on the Nasdaq Global Select Market under the symbol SMTC. For more information, visit www.semtech.com.Senet Contact: Betsey Rogers BridgeView Marketing 603-821-0809 firstname.lastname@example.orgCNIguard Contact: Justen Augustine Associate 212-764-0100 email@example.com Semtech Contact: Ronda Grech Semtech Corporation (805) 250-1263 firstname.lastname@example.org
CAMBRIDGE, Mass., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal imbalance, today announced that Stuart Chaffee, Ph.D., will be transitioning from his current position as the Company's chief financial officer to a part-time role as a strategic advisor to Praxis. The Company has commenced a search for a full-time chief financial officer. Lauren Mastrocola, the Company’s vice president of finance and principal accounting officer, has assumed the responsibilities of principal financial officer on an interim basis. "I’m incredibly proud of what we’ve built at Praxis and consider it a privilege to have helped advance the company through critical milestones,” said Dr. Chaffee. “I look forward to continuing to support Praxis in an advisory role as the company advances towards its next key milestones, while I evaluate opportunities to focus on my passion for building early-stage companies."“On behalf of the leadership team and board of directors, I would like to thank Stuart for his contributions in helping to build Praxis into the company it is today,” said Marcio Souza, president and chief executive officer of Praxis. “I wish him well in returning to his roots in early-stage company development.”About Praxis Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal imbalance. Praxis is applying insights into the genetic mutations that drive excitation-inhibition imbalance in diseases to select biological targets for severe pediatric epilepsies and more broadly for prevalent psychiatric diseases and neurologic disorders. Praxis has established a broad portfolio, including five disclosed programs across multiple central nervous system disorders including depression, epilepsy, movement disorders and pain syndromes, with three clinical-stage product candidates. CONTACT: Investor Contact: Alex Kane Praxis Precision Medicines email@example.com 617-300-8481 Media Contact: Ian Stone Canale Communications Ian.firstname.lastname@example.org 619-849-5388
CHICAGO and VANCOUVER, British Columbia, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Green Thumb Industries Inc. (Green Thumb) (CSE: GTII) (OTCQX: GTBIF), a leading national cannabis consumer packaged goods company and owner of Rise™ retail stores, today announced that its executive team will participate in the following conference in December 2020: Cantor Fitzgerald Cannabis MSO Summit (Virtual), December 15, 2020: Founder and Chief Executive Officer Ben Kovler will participate in a fireside chat.About Green Thumb Industries:Green Thumb Industries Inc. (“Green Thumb”), a national cannabis consumer packaged goods company and retailer, promotes well-being through the power of cannabis while giving back to the communities in which it serves. Green Thumb manufactures and distributes a portfolio of branded cannabis products including Beboe, Dogwalkers, Dr. Solomon’s, incredibles, Rythm and The Feel Collection. The company also owns and operates rapidly growing national retail cannabis stores called Rise™ and Essence. Headquartered in Chicago, Illinois, Green Thumb has 13 manufacturing facilities, licenses for 96 retail locations and operations across 12 U.S. markets. Established in 2014, Green Thumb employs over 2,000 people and serves thousands of patients and customers each year. The company was named a Best Workplace 2018 by Crain’s Chicago Business and MG Retailer magazine in 2018 and 2019. More information is available at GTIgrows.com.Investor Contact:Media Contact: Jennifer DooleyLinda Marsicano Chief Strategy OfficerVP, Corporate Communications InvestorRelations@email@example.com 310-622-8257773-354-2004 Source: Green Thumb Industries
Insurance industry veteran and actuarial expert Matthew Duke to lead the global Actuarial and Analytics Services practice at XceedanceBOSTON, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Xceedance, a global provider of strategic insurance consulting and technology servicing insurance organizations worldwide, today announced the expansion of its global Actuarial and Analytics Services practice, led by Matthew Duke, SVP and chief actuary. “Matthew looks at actuarial services from a business perspective first,” said Manish Khetan, COO of North America operations at Xceedance. “His approach to maximizing the value of the insurance actuarial function can be transformational for large companies looking to streamline and focus operations. Small to mid-size insurance companies, which may not have the bandwidth to truly take advantage of progressive actuarial services, can also benefit from the Xceedance offering.”Duke brings 15 years of leadership in actuarial and analytics disciplines, with expertise in strategy execution, facilitating organizational change, and solving business challenges via data-driven insights that directly impact profitability. He is a member of the American Academy of Actuaries (MAAA), an associate of the Casualty Actuarial Society (ACAS), recognized as an associate in reinsurance (ARe) by The Institutes, and attained his MBA from The Wharton School, University of Pennsylvania. Prior to joining Xceedance, Duke worked at Blackboard Insurance as head of pricing and growth analytics, where he developed actuarial pricing infrastructure, led state filing initiatives, redefined the role of an actuary, and recruited top talent. In addition to interim head of risk at Blackboard, Duke held positions at Freedom Mortgage, Guy Carpenter, Arch Insurance Group, and Travelers.The global Actuarial and Analytics Services capabilities of Xceedance have been expanded by Duke to better align with the strategic objectives and commitments of insurance organizations. The expanded capabilities, featuring advisory, consulting, and enablement services, include: * Staff Enablement * Technology Enablement * Pricing and Growth Analytics * Reserving and Claims Analytics * Data Sciences * Admitted Market Management“Xceedance has provided actuarial services to insurance companies for several years, building a foundation upon which an expanded practice with broader reach can be established,” said Duke. “I strongly believe the involvement of proficient actuaries at all levels of the insurance decision-making process can translate to real value on the profit and loss statement. In partnering with Xceedance, insurance organizations can have access to top-quality actuarial and analytics resources, not only for standard pricing and reserving work, but also to enable other functions which contribute to the goals and outcomes of a company’s strategic plan.”About Xceedance Xceedance (www.xceedance.com) is a global provider of strategic consulting and managed services, technology, data sciences, and blockchain solutions to insurance organizations. Domiciled in Bermuda, with offices in the United States, United Kingdom, Liechtenstein, Switzerland, Poland, India, and Australia, Xceedance helps insurers launch new products, drive operations, implement intelligent technology, deploy advanced analytic capabilities, and achieve business process optimization.Media Contact: Jennifer Overhulse Company: St. Nick Media Telephone: +1 859 803 6597 Email: firstname.lastname@example.org
Figure 1 Nelligan drill hole plan map and highlighted 2020 assay results.MONTRÉAL, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Vanstar Mining Resources (“Vanstar” or the Company) today announces remaining assay results from the 2020 exploration diamond drilling program program completed by its partner IAMGOLD Corporation ("IAMGOLD") at its Nelligan joint venture project (IAMGOLD: 75%, Vanstar: 25%), located 60 kilometres southwest of Chibougamau, Quebec, Canada. The Company is reporting assay results from the final seven (7) diamond drill holes totaling 2,602 metres completed as part of the summer 2020 drilling program. Multiple drill holes returned substantial gold mineralization (up to 7.62 g/t AU) over broad widths. The assay results reported herein are provided in Table 1 below and include the following highlights: (A drill hole plan map is attached to this news release.)Renard West Zone: * Drill hole NE-20-161: 27.0 metres grading 1.11 g/t Au and 36.1 metres grading 1.13 g/t Au and 22.1 metres grading 1.07 g/t Au * Drill hole NE-20-164: 21.8 metres grading 2.00 g/t Au includes: 4.5 metres grading 5.80 g/t Au and 23.2 metres grading 1.72 g/t Au includes: 1.5 metres grading 6.81 g/t AuRenard Zone: * Drill hole NE-20-159: 33.0 metres grading 0.99 g/t Au and 18.0 metres grading 1.55 g/t Au * Drill hole NE-20-162: 17.3 metres grading 7.62 g/t Au (4.49 g/t when capped at 30 g/t) includes: 1.5 metres grading 66.1 g/t Au and 42.0 metres grading 1.15 g/t Au and 15.6 metres grading 1.39 g/t AuLiam Zone: * Drill hole NE-20-160: 8.5 metres grading 4.16 g/t Au includes: 1.3 metres grading 19.8 g/t AuThe Nelligan Gold project (on a 100% basis) hosts Inferred Mineral Resources containing 3.2 million ounces of gold grading 1.02 g/t Au (see news releases dated October 22, 2019 and February 18, 2020). The 2020 diamond drilling program was designed to infill selected areas of the deposit as well as step-out at depth and along strike at the Renard Zone to evaluate the potential for resource extensions.“We are excited to report these excellent results which are accretive to the existing resources estimate and once again demonstrate the potential of the vast gold-bearing hydrothermal system present on the Nelligan property. Our assessments to date lead us to believe that the Nelligan property contains a deposit that has the potential to become economic.’’ said Jonathan Hamel, Interim President and CEO of Vanstar. ‘’The next drilling campaign is expected to begin in January 2021. Our partner IAMGOLD has done excellent work and we are looking forward to the upcoming campaign on Nelligan”.In a separate press release, Craig MacDougall, Executive Vice President, Growth for IAMGOLD, stated: “These remaining results continue to demonstrate continuity of mineralization from the infill drill holes completed in the resource area, and importantly, also continue to demonstrate that mineralization extends well beyond the area of the current modeled resource to the west for at least 500 to 700 metres. The mineralization and associated alteration intersected to date along this western extension appears similar to that observed in the current estimated resource and has potential to expand existing project resources with additional drilling. I must congratulate the exploration team for their perseverance to safely and successfully complete the 2020 exploration program with the numerous challenges posed by the global COVID-19 crisis.”Next Steps With the results of the 2020 exploration drilling program now in hand, data compilation is underway to update the deposit model to help guide future drilling programs. Planning has commenced for the 2021 exploration program, which is expected to include continued drilling to expand the known resources.Additional metallurgical testing is also currently underway to provide further information and help confirm the metallurgical recoveries achieved from previous preliminary test work in order to further refine options for the process flow sheet parameters. Results of this testing program are expected in early 2021.Regional exploration activities and future exploration programs continue to be guided by the ongoing incorporation and compilation of exploration data to refine geological, geochemical and structural models to help identify and prioritize targets for evaluation on the large project land package.About the Nelligan ProjectThe Nelligan project is underlain by a portion of the Caopatina segment of the North Volcanic Zone of the Abitibi Belt of the Superior Province. The property is centered on the E-W Druillette syncline with sediments of the Caopatina Formation bounded to the north and to the south by volcanic rocks of the Obatogamau Formation. The North and South portions of the property are occupied by granodioritic to tonalitic intrusions. The project is transected by numerous regional and local structures and deformation zones which can be important in the localization of gold mineralization.Gold showings of the area are observed broadly as two styles of mineralization: 1) Quartz-sulphide vein type, and 2) disseminated sulphide (pyrite) mineralization in hydrothermally altered units. Mineralization observed on the Nelligan project is dominated by the latter and is characterized by hydrothermal alteration of the host meta-sedimentry units displaying variable carbonatization, sericite, phlogopite and pervasive silicification; and associated with widespread disseminated pyrite, varying from 1% to locally 15%, trace molybdenite and occasionally fine grains of visible gold. Mineralization associated with the estimated mineral resources has been intersected in drilling over a strike length of more than 1.5 kilometre, and to a depth of over 350 vertical metres.As of December 31, 2019, IAMGOLD reported (on a 100% basis) inferred mineral resources of 97.0 million tonnes grading 1.02 g/t Au for 3.2 million contained ounces (see news releases dated October 22, 2019 and February 18, 2020). In 2019 the Nelligan Gold Project was awarded the Discovery of the Year by the Association de l'Exploration Minière du Québec (“AEMQ”).The Nelligan Gold Project is held under an earn-in option to joint venture agreement with Vanstar (IAMGOLD: 75%; Vanstar: 25%) where IAMGOLD has a further option to acquire an additional interest of 5%, to hold an 80% interest in the Nelligan project by completing and delivering a Feasibility Study. Vanstar would then retain a 20% undivided non-contributory carried interest until the commencement of commercial production, after which: (1) the 20% undivided interest becomes participating; and (2) Vanstar will pay its attributable portion of the total development and construction costs to the commencement of commercial production from 80% of its share of any ongoing distributions from the Joint Venture. Vanstar will also retain a 1% NSR royalty on selected claims of the project. Table 1 Nelligan Project Drilling Results - 2020 Drilling program Hole No.UTM NAD83 Zone18AZDIPEOHfromToIntervalTrue Width (1)Au (2) (3)NOTE EastingNorthingElevation(°)(°)(m)(m)(m)(m)(m)(g/t) NE-20-159523028.825473798.75374.34330-50480.00201.00213.0012.0010.391.02RENARD ZONE 220.50226.506.005.200.78 234.00240.006.005.200.87 246.00279.0033.0028.580.99 Including (3) 253.50269.4015.9013.771.42 285.00292.507.506.500.85 304.75328.0023.2514.940.85 363.00364.501.500.962.70 376.50394.5018.0015.591.55 Including (3) 382.50391.509.007.792.58 464.10480.0015.9012.181.15 NE-20-160522937.005473541.05381.11330-5074.0046.5055.008.506.514.16LIAM ZONE Including (3) 52.7053.951.250.9619.75 NE-20-161522122.555473790.66372.10330-48432.0093.00120.0027.0017.361.11RENARD WEST ZONE Including (3) 100.35107.306.954.471.74 145.50154.509.006.360.56 160.50163.503.002.121.63 169.50205.6036.1025.531.13 Including (3) 192.20205.6013.409.481.63 222.10244.1522.0515.591.07 263.65265.151.501.063.41 296.30302.306.004.240.57 NE-20-162522949.825473719.62376.43330-50580.00119.27132.0012.7311.021.44ZONE 36 Including (3) 130.50132.001.501.238.32 189.71207.0017.2914.977.62 (4.49 capped at 30g/t)RENARD ZONE Including (3) 204.00205.501.501.2366.10 217.00234.0017.0013.020.95 265.50286.0020.5015.700.70 322.00340.1218.1213.880.51 348.00390.0042.0032.171.15 428.40444.0015.6011.951.39 491.60516.0024.4018.690.64 526.50530.6184.108.40.206 561.00564.003.002.601.75 NE-20-163 A, B522674.715473502.97376.92330-50181.50Abandonned due to excessive deviation NE-20-164521996.395473697.84375.04330-45450.00150.72172.5021.7814.002.00RENARD WEST ZONE Including (3) 155.00159.504.502.895.80 232.00247.0015.0011.490.58 265.50277.5012.009.190.50 286.50309.7023.2019.001.72 Including (3) 304.30305.801.501.236.81 336.00346.5010.508.600.83 354.00371.5517.5515.200.56 NE-20-165521569.415472937.62380.56330-48404.00No significant results 2,601.50 Notes: 1. True widths are estimated at 64 to 87% of the core interval. 2. Drill hole intercepts are calculated with a lower cut of 0.50 g/t Au and may contain lower grade interval of up to 5 metres in length. They are generally reported with a minimum g*m (or Metal factor) of 5. 3. Assays intervals are reported uncapped and capped at 30 g/t Au and high grade sub-intervals are highlighted. Figure 1 accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/0dadec41-c4f1-49e3-8a8f-1149ad9f4288This press release was read and approved by Mr. Gilles Laverdière, consulting geologist and qualified person under the NI 43-101 Canadian standard.The TSX Venture Exchange and its Regulation Services Provider (as that term is defined in the TSX Venture Exchange Policies) do not accept any responsibility for the truth or accuracy of its content. Source:Jonathan Hamel Interim President and CEO 514-907-9016 x113 email@example.com
Achilles Therapeutics Appoints Robert Coutts as Chief Financial OfficerStevenage, UK 1 December 2020 – Achilles Therapeutics (“Achilles”), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat multiple types of solid tumours, today announced the appointment of Robert Coutts as Chief Financial Officer. Robert has served as Finance Director at Achilles since the Company’s formation in 2017.“Robert has been part of the Achilles team since the beginning and I’m delighted to welcome him to his new role,” said Dr. Iraj Ali, CEO of Achilles Therapeutics. "Robert has deep expertise in building and developing operating businesses. His experience, leadership and commitment to the Company will be integral as our potentially transformative precision TIL therapy progresses in the clinic in multiple solid tumor indications.”“I have been fortunate enough to be a part of the Company's evolution over the last few years, and I look forward to continuing to support Iraj, the management team and Board in our efforts to develop much needed novel cancer therapies for patients,” said Robert Coutts, CFO of Achilles Therapeutics. “As the Company continues to advance its pipeline, the finance function will be an important strategic partner across the Company, including research and development, manufacturing and clinical operations."Prior to joining Achilles, Robert worked for Syncona Ltd leading the finance functions of new entities within its life science portfolio. He previously served in roles of increasing responsibility at the Wellcome Trust. Robert qualified as a chartered accountant with KPMG where he spent time in both their Audit and Transactions & Restructuring teams. He has an MSc in Management from Cass Business School and a BA in Politics, Philosophy and Economics from Oxford University.– Ends –Notes for Editors:About Achilles TherapeuticsAchilles Therapeutics is a clinical stage, biopharmaceutical company developing precision T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell. The Company has two ongoing Phase I/IIa trials, the CHIRON trial in patients with advanced non-small cell lung cancer (NSCLC) and the THETIS trial in patients with recurrent or metastatic malignant melanoma. Achilles uses DNA sequencing data from each patient, together with the proprietary PELEUS™ bioinformatics platform, to identify clonal neoantigens specific to that patient, and then develop personalised T cell-based therapies specifically targeting those clonal neoantigens.For further information please visit the Company’s website at: www.achillestx.com. Further information:Achilles Therapeutics Dr Iraj Ali – Chief Executive Officer +44 (0)1438 906 906 firstname.lastname@example.orgJulia Wilson – Head of Communications +44 (0)7818 430877 email@example.comConsilium Strategic Communications Mary-Jane Elliott, Sukaina Virji, Melissa Gardiner +44 (0) 203 709 5000 firstname.lastname@example.org
ROCKVILLE, Md. and CHESTERBROOK, Pa., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug Application (IND) to study the use of CERC-803 to treat Leukocyte Adhesion Deficiency Type II (LAD II). The company plans to initiate a pivotal trial of CERC-803 in LAD-II (SLC35C1-CDG) by the first half of 2021 and anticipates topline data in the second half of 2021. “There are currently no FDA-approved therapies for patients suffering from LAD-II” said H. Jeffrey Wilkins, MD, Chief Medical Officer of Cerecor. “LAD-II is caused by genetic mutations that result in deficiency in expression of surface adhesion molecule selectin, leading to defective leukocyte functions. This is a pediatric disease with the first symptoms appearing in infancy with recurrent bacterial infections, growth retardation, facial dysmorphism, and severe intellectual deficit as they continue to grow. We are excited to advance this program into the clinic.”The FDA granted Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) to CERC-803, thus potentially qualifying the Company to receive a Priority Review Voucher (PRV) upon approval of a new drug application (NDA).About CERC-800s CERC-801, CERC-802 and CERC-803 are monosaccharide therapies with known therapeutic utility for the treatment of select congenital disorders of glycosylation (CDGs). Oral administration at therapeutic doses of CERC-801, CERC-802, and CERC-803 replenishes critical metabolic intermediates that are reduced or absent due to genetic mutation, overcoming single enzyme defects in respective CDGs to support glycoprotein synthesis, maintenance and function.About Cerecor Cerecor is a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for rare and orphan diseases. The company is advancing its clinical-stage pipeline of innovative therapies that address unmet patient needs within rare and orphan diseases. The company's rare disease pipeline includes CERC-801, CERC-802 and CERC-803 (CERC-800 compounds), which are therapies for inherited metabolic disorders known as congenital disorders of glycosylation. The FDA granted RPDD and ODD to all three CERC-800 compounds, thus potentially qualifying the Company to receive a PRV upon approval of each NDA. The company is also developing CERC-002, CERC-006 and CERC-007. CERC-002 is an anti-LIGHT monoclonal antibody being developed for the treatment of severe pediatric-onset Crohn's disease, and is also being studied for COVID-19 acute respiratory distress syndrome. CERC-006 is a dual mTOR inhibitor being developed for the treatment of complex lymphatic malformations and has been granted ODD and RPDD by the FDA, thus potentially qualifying the company to receive a fourth PRV upon approval of an NDA. CERC-007 is an anti-IL-18 monoclonal antibody being developed for the treatment of autoimmune inflammatory diseases such as Still’s disease and multiple myeloma. For more information about Cerecor, please visit www.cerecor.com.Forward-Looking Statements This press release may include forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to significant risks and uncertainties that are subject to change based on various factors (many of which are beyond Cerecor’s control), which could cause actual results to differ from the forward-looking statements. Such statements may include, without limitation, statements with respect to Cerecor’s plans, objectives, projections, expectations and intentions and other statements identified by words such as “projects,” “may,” “might,” “will,” “could,” “would,” “should,” “continue,” “seeks,” “aims,” “predicts,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential,” or similar expressions (including their use in the negative), or by discussions of future matters such as: the development of product candidates or products; timing and success of trial results and regulatory review; potential attributes and benefits of product candidates; and other statements that are not historical. These statements are based upon the current beliefs and expectations of Cerecor’s management but are subject to significant risks and uncertainties, including: drug development costs, timing and other risks, including reliance on investigators and enrollment of patients in clinical trials, which might be slowed by the COVID-19 pandemic; regulatory risks; Cerecor's cash position and the potential need for it to raise additional capital; general economic and market risks and uncertainties, including those caused by the COVID-19 pandemic; and those other risks detailed in Cerecor’s filings with the Securities and Exchange Commission. Actual results may differ from those set forth in the forward-looking statements. Except as required by applicable law, Cerecor expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Cerecor’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.For media and investor inquiriesJames Harrell Investor Relations Chief Commercial Officer Cerecor Inc. email@example.com 623.439.2220 office
SCOTTSDALE, Ariz., Dec. 01, 2020 (GLOBE NEWSWIRE) -- On December 5th from 7:00am to 10:00am Mountain Standard Time, Whitestone REIT (NYSE: WSR) welcomes “Coffee and Cars” which will showcase approximately 200 cars including: Ferraris, Lamborghinis, Maseratis, McLarens, Porsches, Ford GT40s, and other exotic race cars and collectables. Over 30 race cars that travel over 200 mph will be featured. The event will be held at Whitestone REIT’s Market Street at DC Ranch center, located at 20789 North Pima Road. Whitestone launched the Market Street “Coffee and Cars” Event three months ago, and it has been overwhelmingly embraced by the surrounding community and businesses operating at Whitestone’s Market Street center. Many of the businesses that operate and serve the surrounding community will open early to serve the patrons of the event. At previous “Coffee and Cars” events, many Whitestone tenants have reported seeing their sales increase by 25% or more, and are significantly benefitting from the foot traffic and greater awareness the event brings to their businesses. Attendance is expected to be over 1,000 people of all age groups and plenty of convenient parking is available. Scuderia Southwest co-sponsors the event with Whitestone REIT.Jim Mastandrea, Chairman and CEO of Whitestone REIT commented, “We are pleased to welcome Scuderia Southwest back to our DC Ranch community. This event has increased awareness of our center, and the terrific businesses that operate there, and helped our tenants increase their sales volumes. Whitestone strives to Create Communities that Thrive through Creating Local Connections between consumers and the surrounding communities through these types of events which positively contribute to the overall value of the center and associated tenant businesses. We are pleased to host this fantastic event and the Scuderia Southwest organization.”About Whitestone REIT Whitestone is a community-centered shopping center REIT that acquires, owns, manages, develops and redevelops high-quality neighborhood centers primarily in the largest, fastest-growing and most affluent markets in the Sunbelt. Whitestone seeks to create Communities That Thrive through Creating Local Connections between consumers in the surrounding communities and a well-crafted mix of national, regional and local tenants that provide daily necessities, needed services, entertainment and experiences.Whitestone is a monthly dividend paying stock and has consistently paid dividends for over 15 years. Whitestone’s strong balanced and managed capital structure provides stability and flexibility for growth and positions Whitestone to perform well through economic cycles. For additional information, please visit www.whitestonereit.com.About Scuderia Southwest From its beginning in 2001 as a couple of guys getting coffee, to the current monthly gathering drawing hundreds of truly amazing cars, Scuderia Southwest is a group of people who share a common interest in great automobiles. We put on a few car events, organize a few drives, pull a few g's on the track, and even congregate for a good meal. We love all cars but have a particular passion for rare exotic, high performance and collector cars and our activities typically reflect that. From the 1962 250 GTO to the latest 812 Superfast, we are passionate about Ferraris. From the 1972 Miura to the latest Aventador SV, we love Lamborghinis. The Mercedes 300 SL Gullwing and SLS AMG, McLaren 675LT, Shelby Cobra, D & E-type Jags, and Ford GT are just a few of the special cars we keep in our garages. If you're a car guy or gal, come on out and let's share some coffee, cool stories, and tech talk! For additional information, please visit www.scuderiasouthwest.com .Investors Contact: Kevin Reed, Director of Investor Relations Whitestone REIT (713) 435-2219 firstname.lastname@example.org
– Dr. Liu brings more than 20 years of expertise in pharmaceutical development, formulation, and CMC, with specific focus on lipid-based delivery of complex molecules –BEDMINSTER, N.J., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on developing next generation therapeutics to advance standards of care in areas of significant unmet medical need, today announced the appointment of Hui Liu, Ph.D., M.B.A. as Chief Technology Officer. Dr. Liu joins Matinas with extensive experience in pharmaceutical formulation and delivery technologies, including lipid nanoparticle formulations of mRNA, siRNA and vaccines. In this new role, Dr. Liu will work closely with Raphael Mannino, Ph.D., Matinas’ Chief Scientific Officer, and lead efforts to further strengthen the Company’s proprietary lipid nanocrystal (LNC) drug delivery platform and accelerate its potential applications for both internal programs and external collaborations. “Dr. Liu has spent his career studying, developing, and optimizing drug delivery technologies. His substantial expertise and technical depth complement our existing internal team and fills an essential role in our organization as we look to capitalize upon our proprietary, unique and differentiated LNC delivery platform,” commented Jerome D. Jabbour, Chief Executive Officer of Matinas. “Hui’s accomplishments, especially within the biologics and gene therapy fields, should serve us well as we continue to advance our product candidates and collaborations with an aim to transform the current paradigm for the delivery of innovative medicines.”“I am honored to join the Matinas team and to help accelerate the growth of the Company’s LNC delivery platform,” commented Dr. Liu. “I am very excited by the possibilities of this potentially disruptive technology and I look forward to working closely with the team to deliver our ambitious vision.”Dr. Liu has more than two decades of experience in the formulation of small molecules, biologics, and gene therapies. Dr. Liu joins Matinas directly from Seqirus, a global leader in influenza and pandemic response, where he served as Director of Formulation and Delivery. At Seqirus, Dr. Liu built and led development of lipid nanoparticle technology platforms for next generation gene therapy products. Earlier in his career, Dr. Liu held positions at Cellics Therapeutics, Alcon (a spinoff of Novartis) and Allergan. Dr. Liu is a named inventor on 19 patents related to drug delivery technologies and biodegradable polymers. Dr. Liu holds a Ph.D. in polymer chemistry from the University of Michigan, an M.B.A. from the University of Massachusetts, Amherst, and a B.S. from The University of Science and Technology of China.About Matinas BioPharma Matinas BioPharma is a clinical-stage biopharmaceutical company focused on developing next generation therapeutics to advance standards of care for patients in areas of significant unmet medical need. Company leadership has a deep history and knowledge of drug development and is supported by a world-class team of scientific advisors.MAT9001, the Company’s lead product candidate for the treatment of cardiovascular and metabolic conditions, is a prescription-only omega-3 fatty acid-based composition, comprised primarily of EPA and DPA, under development for hypertriglyceridemia. MAT9001 is currently in a second head-to-head comparative study against Vascepa® (ENHANCE-IT), with topline data expected in the first quarter of 2021.In addition, Matinas is developing a portfolio of products based upon its proprietary lipid nanocrystal (LNC) drug delivery platform, which can solve complex challenges relating to the safe and effective delivery of potent medicines, making them orally bioavailable, less toxic and targeted to cells and tissues. MAT2203, is an oral, encochleated formulation of the well-known, but highly toxic, antifungal medicine amphotericin B, primarily used to treat serious invasive fungal infections. MAT2203 is currently in a Phase 2 open-label, sequential cohort study (EnACT) in HIV-infected patients with cryptococcal meningitis. EnACT is preparing to enroll patients in its second cohort, with the next DSMB evaluation of safety and efficacy data anticipated to occur in the middle of 2021.MAT2501 is an oral, encochleated formulation of the broad-spectrum aminoglycoside antibiotic medicine amikacin, primarily used to treat chronic and acute bacterial infections. The Company recently announced that it has been awarded up to $3.75 million from the Cystic Fibrosis Foundation (CFF) to support development of MAT2501 toward an indication to treat nontuberculous mycobacterial (NTM) lung disease, including infections in patients with cystic fibrosis (CF).Forward Looking StatementsThis release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to the Company’s anticipated capital and liquidity needs, strategic focus and the future development of its product candidates, including MAT9001, MAT2203 and MAT2501, the anticipated timing of regulatory submissions, the anticipated timing of clinical studies, the anticipated timing of regulatory interactions, the Company’s ability to identify and pursue development and partnership opportunities for its products or platform delivery technology on favorable terms, if at all, and the ability to obtain required regulatory approval and other statements that are predictive in nature, that depend upon or refer to future events or conditions. All statements other than statements of historical fact are statements that could be forward-looking statements. Forward-looking statements include words such as "expects," "anticipates," "intends," "plans," "could," "believes," "estimates" and similar expressions. These statements involve known and unknown risks, uncertainties and other factors which may cause actual results to be materially different from any future results expressed or implied by the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to obtain additional capital to meet our liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials of our product candidates; our ability to successfully complete research and further development and commercialization of our product candidates; the uncertainties inherent in clinical testing; the timing, cost and uncertainty of obtaining regulatory approvals; our ability to protect the Company’s intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company’s products; and the other factors listed under "Risk Factors" in our filings with the SEC, including Forms 10-K, 10-Q and 8-K. Investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this release. Except as may be required by law, the Company does not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Matinas BioPharma’s product candidates are all in a development stage and are not available for sale or use.Investor and Media Contacts Peter Vozzo Westwicke 443-213-0505 email@example.comIan Cooney Director – Investor Relations & Corporate Development Matinas Biopharma, Inc. (415) 722-4563 firstname.lastname@example.org
TORONTO, Dec. 01, 2020 (GLOBE NEWSWIRE) -- PharmaTher Inc., a wholly-owned subsidiary of Newscope Capital Corporation (“PharmaTher”) (CSE: PHRM) (OTC Pink: PHRRF) and a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals, is pleased to announce that it has amended its sponsored research agreement with University Health Network (“UHN”) for the development of panaceAI™, the Company’s drug repurposing platform, to also include the development of a digital therapeutics platform to combine with potential psychedelic therapies, including the Company’s ketamine and psilocybin focused product pipeline for disorders of the brain and nervous system. The development work for the Company’s digital therapeutics platform will be conducted by a dedicated research team at Diamandis Lab, which is led by Dr. Phedias Diamandis, MD, PhD, FRCPC, the Principal Investigator who is also advancing the Company’s research with panaceAI™ by merging big data and artificial intelligence to accelerate the drug discovery process.“We are committed to advancing the clinical development of our product pipeline with ketamine and psilocybin while also speeding up the process of finding effective uses of psychedelic-derived medicines with panaceAI™ and complementing them with a digital therapeutic platform to be synergistic with our focus on psychedelic pharmaceuticals,” said Fabio Chianelli, CEO of PharmaTher. “Dr. Diamandis and his research team at UHN, having a rich research program focused on applying artificial intelligence and machine learning to brain disease, are a perfect fit for guiding our digital therapeutics objectives for neurological disorders, such as Parkinson’s disease, depression, neuropathic pain, traumatic brain injury and stroke.”The global digital therapeutics market was valued at US$ 2.69 billion in 2019 and is expected to reach US$ 11.82 billion by 2027.1 According to the Digital Therapeutics Alliance, digital therapeutics deliver evidence-based therapeutic interventions to patients that are driven by high quality software programs to prevent, manage, or treat a medical disorder or disease. They are used independently or in concert with medications, devices, or other therapies to optimize patient care and health outcomes. Digital therapeutics products incorporate advanced technology best practices relating to design, clinical validation, usability, and data security. They are reviewed and cleared or approved by regulatory bodies as required to support product claims regarding risk, efficacy, and intended use. Digital therapeutics empower patients, healthcare providers, and payers with intelligent and accessible tools for addressing a wide range of conditions through high quality, safe, and effective data-driven interventions.2“We are excited to evolve our relationship with PharmaTher for the development and commercialization of a digital therapeutics solution for psychedelic medicines in the treatment of neurological disorders,” said Dr. Diamandis. “My lab has been focused on developing artificial intelligence and machine learning tools directed with the goal of leveraging innovation in technology and digital solutions to address unmet medical needs. Digital therapeutic platforms that can continuously document patients’ biology and symptomatology offer many unique benefits. These include the ability to personalize medication regimens using information gathered both from the individual and big data from large number of patients. The amount of data and feedback you can collect and provide with digital technologies is unprecedented. We are excited to apply these principles and machine learning tools we are developing in the lab for patients with a wide variety of neurological symptoms.”The research program will be led by Dr. Phedias Diamandis, who is an Assistant Professor at the University of Toronto, a Neuropathologist at UHN and a Scientist at Princess Margaret Cancer Centre. His research team focuses on applying innovations in artificial intelligence, big data, tissue bioengineering and large-scale drug profiling, to understand and develop new therapeutic strategies for a wide variety of neurological disorders.Under the agreement, a dedicated team is directed to develop a digital therapeutic platform integrating self-monitoring applications and machine learning to monitor responses and benefits of psychedelic compounds to treat neurological disorders.Psychedelics, such as psilocybin act on the serotonin (5-hydroxytryptamine; 5-HT) 2A receptor and have gained clinical interest as potential therapeutic solutions to address difficult to treat neuropsychiatric disorders such as depression, posttraumatic Stress Disorder (“PTSD”) and addiction. The US Food and Drug Administration (“FDA”) designated both MDMA-assisted psychotherapy for PTSD and psilocybin for treatment-resistant depression as ‘breakthrough therapies’. Non-profit institutions such as Multidisciplinary Association for Psychedelic Studies (“MAPS”), Usona Institute and the Heffter Research Institute as well as academia institutes with dedicated psychedelic and consciousness research centres such as Johns Hopkins University and Imperial College London are also currently focused on the development and clinical research of psychedelic-derived medicines.About PharmaTher Inc.PharmaTher Inc., a wholly-owned subsidiary of Newscope Capital Corporation (CSE: PHRM), is a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals. PharmaTher repurposes psychedelic pharmaceuticals, such as ketamine and psilocybin, for FDA approval to treat disorders of the brain and nervous system. Our goal is to advance the commercialization of panaceAI™, our drug repurposing artificial intelligence platform, and our ketamine focused product pipeline in the treatment of Parkinson’s Disease, depression, and pain. Learn more at: PharmaTher.com and follow us on Facebook, Twitter and LinkedIn.For more information, please contact: Fabio Chianelli Chief Executive Officer PharmaTher Inc. Tel: 1-888-846-3171 Email: email@example.com Website: www.pharmather.comNeither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release. Cautionary StatementThis press release contains ‘forward-looking information’ within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated”, “potential” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Newscope Capital Corporation’s (the “Company) current belief or assumptions as to the outcome and timing of such future events. Forward-looking information in this press release includes information with respect to the development and commercialization of digital therapeutics platform, panaceAI™, psilocybin and ketamine programs and product developments. Forward-looking information is based on reasonable assumptions that have been made by the Company at the date of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information. Given these risks, uncertainties and assumptions, you should not unduly rely on these forward-looking statements. The forward-looking information contained in this press release is made as of the date hereof, and Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The foregoing statements expressly qualify any forward-looking information contained herein. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are described under the caption “Risk Factors” in Company’s management’s discussion and analysis for the period of August 30, 2020 (“MD&A”), dated October 1, 2020, which is available on the Company’s profile at www.sedar.com.This news release does not constitute an offer to sell or the solicitation of an offer to buy, and shall not constitute an offer, solicitation or sale in any state, province, territory or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state, province, territory or jurisdiction.References: 1. Precedence Research. Report on “Digital Therapeutics Market Size, Share, Growth Outlook, Trends, Segment Forecasts, Regional Insights and Forecast 2020 - 2027” (October 2020). 2. Digital Therapeutic Alliance. Digital Therapeutics: Combining Technology and Evidence-based Medicine to Transform Personalized Patient Care (2018).
GREENWICH, Conn., Dec. 01, 2020 (GLOBE NEWSWIRE) -- XPO Logistics, Inc. (NYSE: XPO), a leading global provider of transportation and logistics solutions, today announced a companywide shoe drive to benefit the non-profit organization Soles4Souls. During the month of December, XPO employees will collect new or lightly used shoes to help Soles4Souls aid people living below the poverty line. The shoe drive expands on XPO’s support of Soles4Souls, following the company’s donations of supply chain services earlier this year."Today, on Giving Tuesday, we're launching our December shoe drive to help Soles4Souls bring comfort to children and adults in need," said LaQuenta Jacobs, XPO’s chief diversity officer. “We hope that everyone will celebrate this global day of generosity by making a difference in someone’s life through an act of kindness.”To learn more about Souls4Souls or provide support, please visit soles4souls.org.About XPO Logistics XPO Logistics, Inc. (NYSE: XPO) is a top ten global logistics provider of cutting-edge supply chain solutions to the most successful companies in the world. The company operates as a highly integrated network of people, technology and physical assets in 30 countries, with 1,499 locations and approximately 97,000 employees. XPO uses its network to help more than 50,000 customers manage their goods most efficiently throughout their supply chains. XPO's corporate headquarters are in Greenwich, Conn., USA, and its European headquarters are in Lyon, France. xpo.comAbout Soles4Souls Soles4Souls turns unwanted shoes and clothing into opportunity by putting them to good use: providing relief, creating jobs and empowering people to break the cycle of poverty. With locations across three continents, Soles4Souls has distributed more than 50 million pairs of shoes in 129 countries since 2006. soles4souls.orgMedia Contact XPO Logistics, Inc. Joe Checkler +1-203-423-2098 firstname.lastname@example.org
LONDON, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Gocycle, pioneering urban e-bike brand, is proud to announce that it has been named one of TIME’s 100 Best Inventions of 2020 for its fast-folding Gocycle GXi model. TIME’s annual list celebrates the 100 Best Inventions that are making the world better, smarter, and even a bit more fun. The fast-folding Gocycle GXi went on sale at the start of this year and quickly gained plaudits across the globe, setting a new standard for rider-focused technology in the rapidly growing folding electric bike segment.“We are absolutely delighted with this accolade for our fast-folding GXi – you don’t get much more prestigious than TIME. This award is a testament to the hard work that goes on behind the scenes here at Gocycle. We are driven by the pursuit of designing the world’s best urban electric bikes, taking a no compromises engineering approach to continually improve our products,” said Richard Thorpe, Designer & Founder of Gocycle.The GXi delivers the ultimate blend of design purity, 10-second ultra-fast-folding convenience and exceptional rider fit and riding dynamics. GXi’s stunning array of industry-leading technology includes a patented automotive-inspired Daytime Running Light (DRL), LED cockpit and Gocycle’s electronic predictive shifting.“The challenges of 2020 have given the world a chance to reset and assess how we do things, how we move around and how we look after ourselves. We’ll look back at this year and see it as the moment that e-bikes were propelled into the mainstream,” said Thorpe.2020 Impact on Gocycle Business: TIME’s recognition caps off a year which has seen Gocycle achieve 50% growth in global sales with more people beginning to realise the enormous benefits of electric bikes for healthier and more sustainable journeys.The business has doubled its global workforce over the last 12 months in order to meet the increased demand and to support its exciting future product and growth plans.Thorpe added, “More people than ever are switching onto the enormous health and lifestyle benefits that comes with two-wheeled electric travel. E-bikes will become the dominant form of sustainable personal urban transport and improve the air quality, noise pollution and congestion in our cities.” Gocycle On International Cover of TIME Magazine:For 2020’s list, TIME solicited nominations both from its editors and correspondents around the world and through an online application process. It then evaluated them on factors including originality, effectiveness, ambition and impact.You can see the full list here: time.com/best-inventions-2020The international cover of TIME featuring the 100 Best Inventions of 2020 featuring Gocycle can be viewed here: bit.ly/3lJM8ss Gocycle is available directly at gocycle.com and through select retailers throughout the US, Canada, UK, and EU.About Gocycle Gocycle’s mission is clear: to create the world’s best urban electric bikes. A task which began in earnest in 2002 when former McLaren Cars Limited design engineer Richard Thorpe established his own business, Karbon Kinetics, to embark upon creating his two-wheeled electric dream. Eighteen years on and that dream is a reality with the Gocycle brand renowned the world over for its innovative products, stylish designs and pioneering spirit.You can view and download Gocycle news releases and images on our Gocycle Media Library.Media Contacts:Conrad Allum International PR Manager +44 7701 366 096 email@example.comAllison Matthews Skyya PR 952-836-9626 firstname.lastname@example.org